Eficacia del tratamiento con leuprolide + enzalutamida en pacientes con cáncer de próstata metastásico en el Hospital de Especialidades Dr. Teodoro Maldonado Carbo 2018-2022.

Abstract

The treatment with leuprolide + enzalutamide in metastatic prostate cancer is aimed at inhibiting the role of the androgen receptor, preventing the progression of the disease and decreasing serum PSA values. OBJECTIVE: To assess the results in the treatment of metastatic prostate cancer with leuprolide + enzalutamide. MATERIALS: The IESS AS400 database was used. The data was processed in the IBM-SPSS software. METHODOLOGY: It is a non-experimental, retrospective, observational/descriptive study. RESULTS: there was a decrease in the mean serum PSA levels prior to treatment of 90.6 to 54.1, when comparing them there is a decrease of 36.5; 27% of the patients did not present side effects to the treatment, however 13% presents loss of appetite; the most frequent comorbidity was diabetes mellitus and arterial hypertension; the treatment was more effective in the group of 49 to 60 years. CONCLUSIONS: The treatment with leuprolide + enzalutamide was able to decrease serum PSA levels in patients with metastatic prostate cancer.